Meenakshi Anurag
Assistant Professor
Positions
- Assistant Professor
-
Department of Medicine
ÌÇÐÄÊÓƵ of Medicine
Houston, TX
Addresses
- ÌÇÐÄÊÓƵ of Medicine, 1 Baylor Plaza, BCM-Jewish Institute for Research (Lab)
-
Room 645D,
Houston, TX, 77030
United States
Phone: (713) 798-4298
Education
- PhD from Institute of Genomics & Integrative Biology
- 10/2014 - New Delhi, Delhi, India
- Postdoctoral Fellowship at ÌÇÐÄÊÓƵ of Medicine
- Houston
Professional Interests
- Cancer multi-omics analysis
- Immune informatics
- Breast cancer
Professional Statement
The primary goal of my research is to improve disease diagnosis, treatment and survival by precision data science.
Since my PhD in Bioinformatics, have 7+ years of bioinformatics and data science experience in Cancer research. Cancer is a diverse and heterogeneous disease, hence one therapy will not be uniformly beneficial to all patients. I am also working on rare cancers like Male breast cancer. To dissect the molecular level heterogeneity of these tumors, we employ multi-omics and big data analysis on patient’s next generation sequencing and proteomics data. I implement bioinformatics to understand the role of mutations, structural variations, gene expressions, copy number variations, proteomics and genomic aberrations in promoting cancer.
In the past, I have shown role of DNA damage repair defects as a new class of endocrine treatment resistance driver in breast cancer. Exploring the cause and effect relationship further, we are trying to understanding the contribution of immune-checkpoint and other immune-tolerance factors in therapeutic resistant and advancement of estrogen-receptor positive disease. This warrants for integration of patient genome, transcriptome and metabolome with clinical data.
Since my PhD in Bioinformatics, have 7+ years of bioinformatics and data science experience in Cancer research. Cancer is a diverse and heterogeneous disease, hence one therapy will not be uniformly beneficial to all patients. I am also working on rare cancers like Male breast cancer. To dissect the molecular level heterogeneity of these tumors, we employ multi-omics and big data analysis on patient’s next generation sequencing and proteomics data. I implement bioinformatics to understand the role of mutations, structural variations, gene expressions, copy number variations, proteomics and genomic aberrations in promoting cancer.
In the past, I have shown role of DNA damage repair defects as a new class of endocrine treatment resistance driver in breast cancer. Exploring the cause and effect relationship further, we are trying to understanding the contribution of immune-checkpoint and other immune-tolerance factors in therapeutic resistant and advancement of estrogen-receptor positive disease. This warrants for integration of patient genome, transcriptome and metabolome with clinical data.
Websites
Selected Publications
-
" Clinical Cancer Research. 2018 May ;
Pubmed PMID: . -
" 2019 Oct 30;
Pubmed PMID: . -
" Nature Communications. 2018 Sep ;
Pubmed PMID: . -
" 2020 ;
Pubmed PMID: .
Skills
- Bioinformatics
- NGS-data analysis
- Cancer genomics
- Immune-informatics
- Transcriptomics
to edit your profile